Laboratory of Behavioral Neuroscience, Department of Psychology, School of Social Sciences, University of Crete, Rethymno, Crete, Greece.
Int J Neuropsychopharmacol. 2010 May;13(4):541-8. doi: 10.1017/S1461145709991143. Epub 2010 Jan 5.
The atypical antipsychotic aripiprazole has been demonstrated to reduce symptoms of bipolar mania. To further profile the antimanic-like properties of aripiprazole in relevant preclinical models, we examined its efficacy in d-amphetamine-based behavioural models of acute mania in rats. The effects of acute and repeated administration of aripiprazole were assessed in the facilitation of intracranial self-stimulation (ICSS) and hyperlocomotion after acute d-amphetamine, and in the sensitized facilitation of ICSS function and hyperlocomotion after repeated d-amphetamine. Acutely, aripiprazole (0.75, 1.5 and 2.5 mg/kg i.p.) increased ICSS thresholds, attenuated the reward-facilitating effects of d-amphetamine (0.5 mg/kg i.p.), decreased motor activity and prevented d-amphetamine-induced hyperlocomotion. Co-administration of aripiprazole and d-amphetamine for 7 d resulted in aripiprazole counteracting the d-amphetamine-induced sensitization in facilitation of brain reward function and hyperlocomotion. These results indicate the efficacy of aripiprazole in d-amphetamine-based preclinical models of acute mania that are characterized by increased motivational drive and/or hyperfunction of brain reward.
非典型抗精神病药阿立哌唑已被证明可减轻双相躁狂症的症状。为了进一步描述阿立哌唑在相关临床前模型中的抗躁狂样特性，我们研究了其在大鼠基于安非他命的急性躁狂行为模型中的疗效。评估了阿立哌唑在急性安非他命后促进颅内自我刺激（ICSS）和过度运动，以及在重复安非他命后敏化促进 ICSS 功能和过度运动中的疗效。急性给予阿立哌唑（0.75、1.5 和 2.5 mg/kg 腹腔注射）可增加 ICSS 阈值，减弱安非他命（0.5 mg/kg 腹腔注射）的奖励促进作用，降低运动活性并预防安非他命诱导的过度运动。阿立哌唑和安非他命联合给药 7 天导致阿立哌唑对抗安非他命诱导的大脑奖励功能和过度运动的敏化作用。这些结果表明阿立哌唑在基于安非他命的急性躁狂症的临床前模型中的疗效，这些模型的特征是动机驱动增加和/或大脑奖励功能亢进。
